Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Hologic Selenia 3D Digital Mammography System Gets Panel Nod

This article was originally published in The Gray Sheet

Executive Summary

FDA's Radiological Devices Advisory Panel unanimously endorsed safety and efficacy data on Hologic's Selenia Dimensions 3D three-dimensional digital mammography system for screening and diagnosis of breast cancer at a Sept. 24 meeting

You may also be interested in...



Hologic’s 3-D Mammo: Reimbursement Timing Uncertain Following Approval

Hologic says it is impossible to predict how long it will take to secure reimbursement for its newly approved Selenia Dimensions three-dimensional digital mammography system.

Hologic’s 3-D Mammo: Reimbursement Timing Uncertain Following Approval

Hologic says it is impossible to predict how long it will take to secure reimbursement for its newly approved Selenia Dimensions three-dimensional digital mammography system.

News In Brief

Hologic 3-D mammography approved

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT029430

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel